Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.810
+0.030 (1.69%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Innate Pharma Revenue
In the year 2025, Innate Pharma had annual revenue of 9.01M EUR, down -55.25%. Innate Pharma had revenue of 4.13M in the half year ending December 31, 2025, a decrease of -80.72%.
Revenue (ttm)
9.01M EUR
Revenue Growth
-55.25%
P/S Ratio
16.37
Revenue / Employee
54,909 EUR
Employees
164
Market Cap
173.04M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.01M | -11.12M | -55.25% |
| Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
| Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
| Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
| Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
| Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
| Dec 31, 2019 | 85.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Precision BioSciences | 45.07M |
| Caribou Biosciences | 11.20M |
| Milestone Pharmaceuticals | 1.78M |
| YD Bio | 510.36K |
IPHA News
- 4 weeks ago - Outcome of Innate Pharma's 2026 Annual General Meeting - Business Wire
- 4 weeks ago - Innate Pharma to participate in the Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - Innate Pharma Q1 Earnings Call Highlights - MarketBeat
- 5 weeks ago - Innate Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - Innate Pharma Earnings release: Q1 2026 - Filings
- 5 weeks ago - Innate Pharma Slides: Q1 2026 - Filings
- 5 weeks ago - Innate Pharma Earnings release: Q1 2026 - Filings
- 5 weeks ago - Innate Pharma Slides: Corporate presentation - Filings